Research Grade Bimekizumab (HS856036) is a humanized monoclonal antibody detecting CTLA-8 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights
●Multi-Application — Validated across multiple applications.
种属反应性
Human
应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Protein A/G purified from cell culture supernatant.
Accession号
Q16552 & Q96PD4
状态
Liquid
保存溶液
0.01M PBS pH 7.4
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名
CDP4940, UCB-4940, UCB4940, 1418205-77-2
背景
Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified. • IL-17 and IL-17-producing cells in protection versus pathology., PMID:35790881 • The IL-17 Family of Cytokines in Health and Disease., PMID:30995505 • The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781 • Functional specialization of interleukin-17 family members., PMID:21349428 • Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease., PMID:31866067 • The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases., PMID:37600764 • The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis., PMID:30109481 • Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies., PMID:37373452 • Rhythmic IL-17 production by γδ T cells maintains adipose de novo lipogenesis., PMID:39478228 • Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation., PMID:29275332
Note
For research use only. Not suitable for clinical or therapeutic use.
SEC-HPLC detection for Research Grade Bimekizumab.
Bioactivity
Detects Human IL17A in indirect ELISAs.
Flow Cytometry
Flow-cytometry using anti-human IL17A&IL17F antibody. Jurkat cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an anti-human IL17A&IL17F monoclonal antibody (Catalog HS856036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.
SDS-PAGE
SDS-PAGE for Research Grade Bimekizumab
Western blot
Western blot analysis was performed using anti-IL17A monoclonal antibody at 1μg/ml on various samples. Lane 1: recombinant human IL17A (Catalog No: HS856011), 50ng Lane 2: recombinant human IL17A (Catalog No: HS856011), 30ng Lane 3: recombinant human IL17A (Catalog No: HS856011), 20ng Lane 4: recombinant human IL17A (Catalog No: HS856011), 10ng
